MX2016008355A - Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos. - Google Patents
Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.Info
- Publication number
- MX2016008355A MX2016008355A MX2016008355A MX2016008355A MX2016008355A MX 2016008355 A MX2016008355 A MX 2016008355A MX 2016008355 A MX2016008355 A MX 2016008355A MX 2016008355 A MX2016008355 A MX 2016008355A MX 2016008355 A MX2016008355 A MX 2016008355A
- Authority
- MX
- Mexico
- Prior art keywords
- conjugates
- light chain
- antibodies
- present disclosure
- methods
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 abstract 2
- 210000004899 c-terminal region Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0039—Coumarin dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920425P | 2013-12-23 | 2013-12-23 | |
| PCT/CA2014/051263 WO2015095972A1 (en) | 2013-12-23 | 2014-12-23 | Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016008355A true MX2016008355A (es) | 2016-10-28 |
Family
ID=53477259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008355A MX2016008355A (es) | 2013-12-23 | 2014-12-23 | Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11208497B2 (OSRAM) |
| EP (1) | EP3087185A4 (OSRAM) |
| JP (1) | JP6585600B2 (OSRAM) |
| KR (1) | KR20160122127A (OSRAM) |
| CN (1) | CN106459981A (OSRAM) |
| AU (1) | AU2014373593B2 (OSRAM) |
| BR (1) | BR112016014913A8 (OSRAM) |
| CA (1) | CA2934818C (OSRAM) |
| IL (1) | IL246371A0 (OSRAM) |
| MX (1) | MX2016008355A (OSRAM) |
| RU (1) | RU2016129724A (OSRAM) |
| SG (1) | SG11201605093VA (OSRAM) |
| WO (1) | WO2015095972A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10780182B2 (en) | 2014-04-25 | 2020-09-22 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
| EP3526257A2 (en) * | 2016-10-14 | 2019-08-21 | Dana-Farber Cancer Institute, Inc. | Modular tetravalent bispecific antibody platform |
| JP2020506971A (ja) | 2017-02-08 | 2020-03-05 | ドラゴンフライ セラピューティクス， インコーポレイテッド | ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用 |
| SG11201907646YA (en) | 2017-02-20 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding her2, nkg2d and cd16 |
| US11607457B2 (en) | 2017-07-13 | 2023-03-21 | City Of Hope | Anti-cancer phosphorothioate-coupled peptide conjugates and methods of using the same |
| US11541121B2 (en) | 2017-07-13 | 2023-01-03 | City Of Hope | Phosphorothioate-conjugated peptides and methods of using the same |
| KR20240167101A (ko) * | 2017-09-07 | 2024-11-26 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 넥틴4에 결합하는 단백질 |
| PE20210375A1 (es) | 2018-02-08 | 2021-03-02 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales |
| FI3749346T3 (fi) | 2018-02-08 | 2024-09-04 | Dragonfly Therapeutics Inc | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät |
| MX2020008684A (es) | 2018-02-20 | 2020-12-07 | Dragonfly Therapeutics Inc | Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso. |
| SG11202010439VA (en) | 2018-05-01 | 2020-11-27 | Ambrx Inc | A method for optimizing antibody expression |
| JP7482363B2 (ja) | 2018-08-08 | 2024-05-14 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| US12384851B2 (en) | 2018-08-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use |
| CN113453725A (zh) | 2018-11-30 | 2021-09-28 | 百时美施贵宝公司 | 包含含有谷氨酰胺的轻链c末端延伸的抗体、其缀合物以及方法和用途 |
| TW202208428A (zh) | 2020-05-06 | 2022-03-01 | 美商蜻蜓醫療公司 | 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| CN115947830B (zh) * | 2022-12-27 | 2023-09-12 | 优洛生物(上海)有限公司 | 一种经改造的抗体、其制备方法及其用途 |
| EP4548936A1 (en) | 2023-10-30 | 2025-05-07 | BioNTech SE | Antibody-drug conjugates having a tailor-made drug-to-antibody ratio |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2170589C2 (ru) | 1992-10-28 | 2001-07-20 | Генентек Инк. | Композиция для ингибирования ангиогенеза, моноклональное антитело, полипептид, способ ингибирования роста опухоли (варианты) |
| WO1994011028A1 (en) * | 1992-11-16 | 1994-05-26 | Centocor, Inc. | Compounds having reduced immunogenicity and a method of reducing the immunogenicity of compounds |
| US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| US20050159343A1 (en) | 1999-03-26 | 2005-07-21 | Board Of Regents, University Of Texas System | Inhibitors of glycosaminoglycans |
| JP2005500002A (ja) | 2000-10-02 | 2005-01-06 | エリゼク・ファーマシュウティカルズ・インコーポレイテッド | 生物学的に活性な薬剤を細胞関門を越えて輸送するための組成物および方法 |
| US7834258B2 (en) * | 2003-06-30 | 2010-11-16 | Mu-Hyeon Choe | Dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same |
| WO2007103288A2 (en) * | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
| AU2007257692B2 (en) * | 2006-06-12 | 2013-11-14 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
| AR067543A1 (es) * | 2007-07-16 | 2009-10-14 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso |
| US20090155275A1 (en) | 2007-07-31 | 2009-06-18 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| WO2009026274A1 (en) * | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| DE112008003232T5 (de) * | 2007-11-30 | 2011-02-24 | Glaxo Group Limited, Greenford | Antigen-Bindungskonstrukte |
| WO2009088805A2 (en) | 2008-01-03 | 2009-07-16 | The Scripps Research Institute | Antibody targeting through a modular recognition domain |
| US8454960B2 (en) * | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| AU2009303318B2 (en) * | 2008-10-10 | 2016-06-30 | Aptevo Research And Development Llc | TCR complex immunotherapeutics |
| US8734796B2 (en) * | 2009-03-20 | 2014-05-27 | Amgen Inc. | Carrier immunoglobulins |
| WO2012059882A2 (en) | 2010-11-05 | 2012-05-10 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| WO2012153193A2 (en) * | 2011-05-08 | 2012-11-15 | Legochem Biosciences, Inc. | Protein-active agent conjugates and method for preparing the same |
| ES2704038T3 (es) | 2011-05-24 | 2019-03-13 | Zyngenia Inc | Complejos multiespecíficos multivalentes y monovalentes y sus usos |
| ES2667864T3 (es) * | 2011-06-22 | 2018-05-14 | F. Hoffmann-La Roche Ag | Eliminación de células diana mediante linfocitos T citotóxicos específicos de virus en circulación usando complejos que comprenden MHC de clase I |
| CA2854806A1 (en) * | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| WO2013096829A2 (en) | 2011-12-22 | 2013-06-27 | Arizona Biomedical Research Commission | Activation of cellular assault processes in the treatment of glioblastoma multiforme |
| WO2013128031A1 (en) * | 2012-03-02 | 2013-09-06 | Ablynx Nv | Pseudomonas aeruginosa pcrv binding single variable domain antibodies |
| TW201427989A (zh) | 2012-12-18 | 2014-07-16 | Novartis Ag | 長效性蛋白質之組合物及方法 |
-
2014
- 2014-12-23 RU RU2016129724A patent/RU2016129724A/ru unknown
- 2014-12-23 WO PCT/CA2014/051263 patent/WO2015095972A1/en not_active Ceased
- 2014-12-23 CN CN201480075958.5A patent/CN106459981A/zh active Pending
- 2014-12-23 AU AU2014373593A patent/AU2014373593B2/en active Active
- 2014-12-23 BR BR112016014913A patent/BR112016014913A8/pt not_active Application Discontinuation
- 2014-12-23 SG SG11201605093VA patent/SG11201605093VA/en unknown
- 2014-12-23 KR KR1020167019769A patent/KR20160122127A/ko not_active Withdrawn
- 2014-12-23 JP JP2016543004A patent/JP6585600B2/ja active Active
- 2014-12-23 US US15/107,884 patent/US11208497B2/en active Active
- 2014-12-23 MX MX2016008355A patent/MX2016008355A/es unknown
- 2014-12-23 EP EP14874786.8A patent/EP3087185A4/en not_active Withdrawn
- 2014-12-23 CA CA2934818A patent/CA2934818C/en active Active
-
2016
- 2016-06-21 IL IL246371A patent/IL246371A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160122127A (ko) | 2016-10-21 |
| RU2016129724A3 (OSRAM) | 2018-10-18 |
| EP3087185A1 (en) | 2016-11-02 |
| AU2014373593A1 (en) | 2016-07-14 |
| EP3087185A4 (en) | 2017-09-06 |
| IL246371A0 (en) | 2016-08-31 |
| WO2015095972A1 (en) | 2015-07-02 |
| AU2014373593B2 (en) | 2020-07-16 |
| BR112016014913A8 (pt) | 2020-06-09 |
| RU2016129724A (ru) | 2018-01-30 |
| JP6585600B2 (ja) | 2019-10-02 |
| JP2017501728A (ja) | 2017-01-19 |
| CN106459981A (zh) | 2017-02-22 |
| BR112016014913A2 (OSRAM) | 2017-08-08 |
| US11208497B2 (en) | 2021-12-28 |
| CA2934818C (en) | 2022-05-17 |
| US20170008970A1 (en) | 2017-01-12 |
| CA2934818A1 (en) | 2015-07-02 |
| SG11201605093VA (en) | 2016-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016008355A (es) | Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos. | |
| PH12018502601A1 (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
| PH12020550690A1 (en) | Radiolabeling of polypeptides | |
| MX2017006866A (es) | Pares de unión para producción de péptidos. | |
| MX2022010324A (es) | Sitios especificos para modificar anticuerpos para hacer inmunoconjugados. | |
| MX2018015285A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
| MX2018015277A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
| TR201809571T4 (tr) | Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri. | |
| MX2017003123A (es) | Anticuerpos y conjugados modificados geneticamente con cisteina. | |
| NZ734892A (en) | Amatoxin-antibody conjugates | |
| SA520412669B1 (ar) | تصنيع ذيفانات عصبية ناتجة عن معاودة الارتباط الجيني من المطثية الوشيقية | |
| EP3960767A3 (en) | Specific sites for modifying antibodies to make immunoconjugates | |
| TN2015000085A1 (en) | Fc containing polypeptides with altered glycosylation and reduced effector function | |
| SA112330988B1 (ar) | أجسام مضادة تخص trop-2 واستخداماتها | |
| WO2013184938A3 (en) | Fusion polypeptides comprising mucin-domain polypeptide linkers | |
| CY1115091T1 (el) | Διειδικες πρωτεϊνες προσδεσης αντιγονων | |
| UA112416C2 (uk) | Антитіло до fap і способи його застосування | |
| MX360741B (es) | Constructos de polipéptidos y sus usos. | |
| UA117493C2 (uk) | Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання | |
| MX366178B (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. | |
| SG10201805039UA (en) | Protease resistant peptides | |
| AR075933A1 (es) | Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso | |
| PL417544A1 (pl) | Sposób modyfikacji sekwencji polipeptydów oraz jej zastosowanie | |
| WO2014152831A3 (en) | Targeting peptides and uses thereof | |
| MX2009011851A (es) | Plasmidos de dna que tienen expresion y estabilidad mejoradas. |